TDF reduces HBV DNA burden and liver immune microenvironment in CHB patients

Summary

The first source discusses the effectiveness of oral antiviral medications for Hepatitis B (HBV). While these medications are primarily thought to inhibit viral replication, recent studies show that they may also play a role in reducing the amount of viral DNA within the liver. This finding challenges the traditional view that these medications only prevent new infections. The second source provides evidence from a study that shows how tenofovir disoproxil fumarate (TDF), an antiviral medication, impacts the liver's immune microenvironment in HBV patients with mild liver damage. This study reveals that TDF treatment significantly reduces the amount of both integrated and non-integrated HBV DNA within the liver, suggesting that it may be more effective than previously thought. The third source highlights the characteristics of HBV integration in pediatric patients with chronic HBV infection. This study suggests that integration is more common in children compared to adults and may contribute to the accelerated loss of HBsAg in pediatric patients.

Sources:

https://gut.bmj.com/content/early/2024/10/08/gutjnl-2024-332526